GuidelinesOther guideline
SARAA Eligibility Criteria for b/tsDMARD Therapies for PsA
Polyarthritis treated with at least two conventional DMARDs (maximal dosages, sequentially or in combination) with lack of improvement (50% of DAPSA) within 3 months or failure to achieve MDA within 6 months. Severe persistent oligoarthritis with a major demonstrable influence on wellbeing of the patient where treatment has failed, with at least two csDMARDs and appropriate intra-articu
- Polyarthritis treated with at least two conventional DMARDs (maximal dosages, sequentially or in combination) with lack of improvement (50% of DAPSA) within 3 months or failure to achieve MDA within 6 months.
- Severe persistent oligoarthritis with a major demonstrable influence on wellbeing of the patient where treatment has failed, with at least two csDMARDs and appropriate intra-articular therapy with lack of improvement within 3 months or failure to achieve MDA within 6 months.
- Axial disease with poor response to NSAIDs (as per SARAA recommendation for axSpA).
- Refractory dactylitis, enthesitis or extra-articular disease.
Benitha, R., Maharaj, A. B., Makan, K., Potts, J., Lai, A., Carter, R., van Dam, M., & Hodkinson, B. (2024). South African Rheumatism and Arthritis Association 2024 guidelines for the management of peripheral spondyloarthritis. South African Medical Journal, 114(10), e2669.